Bharat Biotech's Covaxin can neutralise the '617' variant of the deadly virus, says Fauci

Covaxin, India's home-grown COVID-19 vaccine, has been found to neutralise the 617 variant of the deadly virus, White House chief medical adviser and America's top pandemic expert Dr Anthony Fauci said here.

Fauci was speaking to reporters during a conference call on Tuesday.

"This is something where we're still gaining data on a daily basis. But the most recent data, was looking at convalescent Sera of COVID-19 cases and people who received the vaccine used in India, the Covaxin. It was found to neutralise the 617 variants," he said.

"So, despite the real difficulty that we're seeing in India, vaccination could be a very, very important antidote against this," Fauci added.

The New York Times on Tuesday said Covaxin works by teaching the immune system to make antibodies against the SARS-CoV-2 coronavirus. The antibodies attach to viral proteins, such as the so-called spike proteins that stud its surface.

Developed by Bharat Biotech in partnership with National Institute of Virology and the Indian Council of Medical Research, Covaxin was approved for emergency use on January 3. Trial results later showed the vaccine has an efficacy of 78 per cent.

Responding to a question, Dr Andy Slavitt, White House COVID-19 Response Senior Advisor, said that a strike team from the Center for Disease Control and Prevention is headed over to India to help coordinate this response.

"We are making sure that we are locating some of the raw materials necessary to create more vaccines in India, which I think is going to be an important help there," he said.

"We stand with the country of India during this very trying and tragic surge. We are working to deploy resources and supplies, including therapeutics, rapid testing kits, ventilators, PPE, and raw materials, that are needed to manufacture vaccines in India, and the CDC, which has a long history of working with and in India on public health measures, will be deploying a strike team to the country to support the public health efforts there," Slavitt said.

Given the strong portfolio of approved, highly effective and safe vaccines here in the United States, the administration is looking at options to share AstraZeneca vaccines with other countries as they become available.

This should amount to around 60 million doses or so over the next two months, he added.

"The AstraZeneca vaccine is highly safe and effective, and approved in many parts of the world, and since it is not approved for use in the US, we do not need to use the AstraZeneca vaccine here during the next few months," Slavitt said.

"We have sufficient supply of vaccines from Pfizer, Moderna, and Johnson & Johnson to accommodate our needs in the US," he added.


SEE ALSO:
Favipiravir shortage may get filled up in a couple of weeks provided people don't hoard
India will receive the first batch of Sputnik V COVID-19 vaccine by May 1 — in time for the third phase of its vaccination drive
WHO is ‘doing everything’ to help India with its COVID-19 crisis as GAVI waits for vaccine exports to begin again
Election Commission bans all victory processions on or after counting on May 2